- 专利标题： CD80 and CD86 Binding Protein Compositions and Uses Thereof
-
申请号： US16333888申请日： 2017-09-19
-
公开(公告)号： US20190263889A1公开(公告)日： 2019-08-29
- 发明人: Yang LIU , Pan ZHENG , Martin DEVENPORT , Wei WU , Xuexiang DU , Mingyue LIU , Fei TANG
- 申请人： ONCOIMMUNE, INC. , CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
- 申请人地址： US MD Rockville US DC Washington
- 专利权人： ONCOIMMUNE, INC.,CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
- 当前专利权人： ONCOIMMUNE, INC.,CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
- 当前专利权人地址： US MD Rockville US DC Washington
- 国际申请： PCT/US2017/052264 WO 20170919
- 主分类号： C07K14/705
- IPC分类号： C07K14/705 ; C07K16/28 ; A61P35/00 ; A61P37/06
摘要：
This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.
公开/授权文献
- US11261233B2 CD80 and CD86 binding protein compositions and uses thereof 公开/授权日：2022-03-01
信息查询
